Wang T B, Li Z, Zhao D B
Department of Pancreatic and Gastric Surgery, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2023 May 25;26(5):419-422. doi: 10.3760/cma.j.cn441530-20230117-00016.
Peritoneal metastasis of gastric cancer serving as the most frequent form of metastasis, is one of the leading causes of death. A portion of surgically treated patients often suffer from small peritoneal residual metastasis, which will lead to recurrence and metastasis of gastric cancer patients after surgery. Given these, the prevention and treatment of peritoneal metastasis of gastric cancer deserves more attention. Molecular residual disease (MRD) refers to the molecular abnormalities of tumor origin that cannot be found by traditional imaging or other laboratory methods after treatment, but can be found by liquid biopsy, representing the possibility of tumor persistence or clinical progress. In recent years, the detection of MRD based on ctDNA has gradually become a research hotspot in the prevention and treatment of peritoneal metastasis. Our team established a new method for MRD molecular diagnosis of gastric cancer, and reviewed the research achievements in this field.
胃癌腹膜转移作为最常见的转移形式，是主要的死亡原因之一。一部分接受手术治疗的患者常伴有微小的腹膜残留转移灶，这会导致胃癌患者术后复发和转移。鉴于此，胃癌腹膜转移的防治值得更多关注。分子残留病灶（MRD）是指肿瘤来源的分子异常，在治疗后通过传统影像学或其他实验室方法无法检测到，但可通过液体活检检测到，代表肿瘤持续存在或临床进展的可能性。近年来，基于循环肿瘤DNA（ctDNA）检测MRD逐渐成为腹膜转移防治领域的研究热点。我们团队建立了一种新的胃癌MRD分子诊断方法，并对该领域的研究成果进行了综述。
